Added benefit of eribulin in breast cancer is not proven
'Hints' for longer survival only in specific patients; greater harm cannot be excluded
2012-08-16
(Press-News.org) Eribulin (trade name: Halaven®) was approved in March 2011 for women with locally advanced or metastasizing breast cancer in whom the disease has progressed despite prior drug therapy.
In an early benefit assessment pursuant to the "Act on the Reform of the Market for Medicinal Products" (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether eribulin offers an added benefit compared with the present standard therapy.
According to the results of the assessment, the currently available evidence provides "hints" that eribulin may increase survival time in patients for whom taxanes or anthracyclines are no longer an option. However, it is unclear how many more weeks or months patients can survive. No survival advantage was shown in patients who can still be treated with taxanes or anthracyclines. At the same time, due to a lack of suitable data it cannot be excluded with sufficient certainty that eribulin causes greater harm in the form of side effects. Overall, IQWiG therefore concludes that an added benefit of eribulin is not proven.
G-BA specifies appropriate comparator therapy
According to the legal ordinance, benefit assessments must follow the approval status. This refers both to the new drug to be evaluated and to the therapies used in the comparator groups.
Eribulin is approved for patients in whom the disease has progressed further, despite having received at least two cycles of a taxane and anthracycline containing chemotherapy (unless these treatments were considered unsuitable). As appropriate comparator therapies, the Federal Joint Committee (G-BA) has specified either monotherapy with capecitabine, 5-fluorouracil, or vinorelbine or renewed therapy with taxanes or anthracyclines, insofar as this is an option for patients.
The pharmaceutical company followed this specification of the appropriate comparator therapy. However, by the wording of the research question and the inclusion criteria of the dossier, the company also allowed other treatments as a comparator therapy for eribulin.
One study included in the assessment
One relevant study was available for the early benefit assessment, an approval study on eribulin (EMBRACE). However, drugs that were not a component of the appropriate comparator therapy were also used in this study. 18% of patients even received treatment that is not approved in Germany for the indication investigated (gemcitabine monotherapy).
Overall, only 69% of patients in the comparator group were treated according to the specifications of the G-BA. Nevertheless, in the dossier the manufacturer uses the results of all patients (overall population). This is an approach that IQWiG cannot accept.
No survival advantage in patients who can still be treated with taxanes or anthracyclines
Data on overall survival and side effects (adverse events), but not on quality of life, were analysed in the study, so that per se no conclusions about the latter outcome are possible.
For the outcome "overall survival", separate data were available for the sub-population treated with the appropriate comparator therapy. As the analysis showed, patients in the eribulin group for whom treatment with taxanes or anthracyclines could still be an option did not survive longer than patients who received these treatment alternatives. An added benefit is therefore not proven.
"Hint" of an increase in survival in patients for whom taxanes or anthracyclines are no longer an option
The situation is different in patients for whom taxanes or anthracyclines are no longer an option. The data show a survival advantage here, at least for the first time point of analysis. In contrast, statistically significant differences were no longer observed between treatment groups at a second, later time point of analysis. It cannot be calculated exactly how many weeks or months longer patients receiving eribulin survived. However, the difference in the study was not more than a few months.
From the data analysed, IQWiG initially infers a "hint" of an added benefit in patients for whom treatment with taxanes or anthracyclines is no longer an option; the extent of this added benefit is unquantifiable but can at best be classified as "considerable".
No separate data on adverse events in the sub-population
In contrast to the outcome "overall survival", data on side effects (adverse events) were only available for the overall population; no separate data were provided for the sub-population treated with one of the appropriate comparator therapies specified. In its assessment, IQWiG additionally investigated the data for the overall population in order to obtain an impression of potential harm caused by the interventions.
According to the results, both the overall rate of adverse events and the rate of severe adverse events were statistically significantly higher in the eribulin group than in the comparator group. IQWiG infers from these results that greater harm from eribulin cannot be excluded with sufficient certainty for the sub-population investigated in the dossier assessment.
Negative effects may outweigh positive ones
Overall IQWiG cannot infer an added benefit of eribulin from the data available. This also applies to the sub-group of patients for whom taxanes or anthracyclines are no longer an option. This is because it cannot be excluded that the negative effects (severe adverse events) outweigh the positive effects (survival). It cannot be excluded that eribulin may even be more harmful than beneficial in patients who could still be treated with taxanes or anthracyclines.
G-BA decides on the extent of added benefit
The procedure for inferring the overall conclusion on the extent of added benefit is a proposal from IQWiG. The G-BA, which has opened a formal commenting procedure, decides on the extent of added benefit.
The following extract (PDF, 186 kB) provides an overview of the results of IQWiG's benefit assessment. The website gesundheitsinformation.de, which is issued by IQWiG, provides easily understandable brief information (German version).
The G-BA website contains both general information on benefit assessments pursuant to §35a Social Code Book V and specific information on the assessment of eribulin (German version).
INFORMATION:
END
ELSE PRESS RELEASES FROM THIS DATE:
2012-08-16
COLUMBUS, Ohio - Almost 41 percent of Ohioans have visited a lake, pond, river or creek in the state in the past year, and of those, nearly one-half usually spend their water-related recreational time at Lake Erie, according to preliminary findings in a new report.
These figures and other findings in the report suggest that Ohio residents value their lakes and rivers, and particularly Lake Erie, as natural resources, but also help to clarify the risk that Ohioans face from contaminants in those same bodies of water, researchers say.
Among the risks: Some blue-green ...
2012-08-16
PROVIDENCE, R.I. – A Rhode Island Hospital researcher has found that the use of electronic prescription drug monitoring programs (PMPs) may have a significant impact on the demand for drug treatment programs and how prescribers detect and respond to abuse of painkillers. The study by Traci C. Green, Ph.D., MSc, research scientist in Rhode Island Hospital's department of general internal medicine, is published online in advance of print in the journal Pain Medicine.
The study surveyed 1,385 providers in Rhode Island and Connecticut on their use of state PMPs, and found ...
2012-08-16
Results of a phase III clinical trial of the drug Enzalutamide, published yesterday in the New England Journal of Medicine, show the drug extends life by an average five months in the most advanced stages of prostate cancer.
"This is a major advance. Not only do we see more survival benefit than from traditional chemotherapy, but the side effects of Enzalutamide are much lower. It provides both more benefit and less harm – you get the quantification of more life, but also see quality of life improvements," says study co-author, Thomas Flaig, MD, medical director of the ...
2012-08-16
Quantum computers promise to reach computation speeds far beyond that of today's computers. As they would use quantum effects, however, they would also be susceptible to external interferences. Information flow into and out of the system is a critical point. Researchers from KIT with partners from Grenoble and Strasbourg have now read out the quantum state of an atom directly by using electrodes. In the Nature journal, it is reported about the stable interface between classical and quantum world. (DOI: 10.1038/nature11341)
"Normally, every contact with the outer world ...
2012-08-16
Chapel Hill, NC – Leukemia and lymphoma patients who receive life-saving stem cell or bone marrow transplants often experience chronic side effects that significantly decrease quality of life, can last a lifetime, and ultimately affect their long-term survival.
In chronic Graft vs. Host Disease (GVHD), the differences between the donor bone marrow cells and the recipient's body often cause these immune cells to recognize the recipient's body tissues as foreign and the newly transplanted cells attack the transplant recipient's body. Symptoms can range from dry eyes and ...
2012-08-16
While your DNA is unique, it also tells the tale of your family line. It carries the genetic history of your ancestors down through the generations. Now, says a Tel Aviv University researcher, it's also possible to use it as a map to your family's past.
Prof. Eran Halperin of TAU's Blavatnik School of Computer Science and Department of Molecular Microbiology and Biotechnology, along with a group of researchers from University of California, Los Angeles, are giving new meaning to the term "genetic mapping." Using a probabilistic model of genetic traits for every coordinate ...
2012-08-16
CHAMPAIGN, Ill. — Birds of a feather flock together and – according to a new analysis – so do their lice.
A study of the genetic heritage of avian feather lice indicates that their louse ancestors first colonized a particular group of birds (ducks or songbirds, for example) and then "radiated" to different habitats on those birds – to the wings or heads, for instance, where they evolved into different species. This finding surprised the researchers because wing lice from many types of birds look more similar to one another than they do to head or body lice living on the ...
2012-08-16
New Rochelle, NY, August 16, 2012—Every year tribal gaming generates billions of dollars in revenue, creates tens of thousands of jobs, and boosts the economies of many Native American communities. In the state of California alone, tribal gaming has brought in $7.5 billion annually. However, because of the aggressive movement to legalize Internet gambling, which effectively would give states the power to regulate and tax online gambling even on reservations, the financial success of these communities could change. In "Native American Off-Reservation Gaming," an expert roundtable ...
2012-08-16
After a surgeon stitches up a patient's abdomen, costly complications -- some life-threatening -- can occur. To cut down on these postoperative problems, Johns Hopkins undergraduates have invented a disposable suturing tool to guide the placement of stitches and guard against the accidental puncture of internal organs.
The student inventors have described their device, called FastStitch, as a cross between a pliers and a hole-puncher. Although the device is still in the prototype stage, the FastStitch team has already received recognition and raised more than $80,000 ...
2012-08-16
Ancient pollen and charcoal preserved in deeply buried sediments in Egypt's Nile Delta document the region's ancient droughts and fires, including a huge drought 4,200 years ago associated with the demise of Egypt's Old Kingdom, the era known as the pyramid-building time.
"Humans have a long history of having to deal with climate change," said Christopher Bernhardt, a researcher with the U.S. Geological Survey. "Along with other research, this study geologically reveals that the evolution of societies is sometimes tied to climate variability at all scales – whether decadal ...
LAST 30 PRESS RELEASES:
[Press-News.org] Added benefit of eribulin in breast cancer is not proven
'Hints' for longer survival only in specific patients; greater harm cannot be excluded
